好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Early Infarct Growth Rate is Correlated with IV Thrombolysis Outcomes in Telestroke Patients
Cerebrovascular Disease and Interventional Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
13-002

Evaluate if Early Infarct Growth Rate (EIGR) can be used to predict outcome in telestroke patients treated with IV thrombolysis.

CT Perfusion (CTP) can aid in thrombectomy decision making in patients with acute ischemic stroke. Fast progressors defined by EIGR have been correlated with worse outcomes after thrombectomy.

We retrospectively analyzed consecutive telestroke patients with a baseline modified Rankin Scale score (mRS) ≤2 and received CTP prior to IV thrombolysis, between July 2019 and June 2021. We compared outcomes of fast (EIGR ≥10mL/h) versus slow (EIGR <10mL/h) progressors treated with thrombolysis.  Primary efficacy and safety outcomes were: functional independence at 90 days (mRS 0–2) and major hemorrhage ≤36h post-thrombolysis.  Secondary outcomes included excellent functional recovery (mRS 0–1), and death at 90 days.  Primary and secondary outcomes were analyzed using multivariable binary logistic regression models in two blocks.  The first block proceeded by stepwise fashion and included possible confounding variables as determined by univariate analyses and prior research, followed by the variable of interest: EIGR (<10ml/h; ≥10mL/h).

There were 2767 telestroke consults during the study period and 261 (9.4%) were treated with IV thrombolysis. A total of 146 patients had baseline mRS ≤2, received CTP prior to IV thrombolysis and were included in this study. Fast progressors were less likely to attain functional independence at 90 days compared to slow progressors [7(41.2%) vs 109(84.5%)], adjusted odds ratio (aOR)=0.22 [95%CI, 0.06–0.85], p=0.03,  but no difference in major hemorrhage rate between fast and slow progressors, [1(5.9%) vs 2(1.6%)], p=0.48.  Fast progressors had lower rates of excellent functional recovery, [5(31.3%) vs 94(78.3%)], aOR=0.15 [95%CI, 0.04–0.58], p=0.006, and higher rates of death at 90 days, [4(23.5%) vs 4(3.1%)], aOR=9.62 [95%CI, 2.15–43.05], p=0.003.

IV Thrombolysis treated telestroke patients defined by EIGR as fast progressors had worse outcomes at 90 days.

Authors/Disclosures
Chris Hackett, MA
PRESENTER
Mr. Hackett has nothing to disclose.
Maulik Kantawala, MD (AHN) Dr. Kantawala has nothing to disclose.
Konark Malhotra, MD (Allegheny Health Network) Dr. Malhotra has nothing to disclose.
Sandeep S. Rana, MD, FAAN (Allegheny Health Network) Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSI. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pharmawrite. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for amylyx. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion.
David G. Wright, MD Dr. Wright has nothing to disclose.
No disclosure on file
Timothy Quezada, MD (Allegheny General Hospital - Neurology) Dr. Quezada has nothing to disclose.
Ashis H. Tayal, MD Dr. Tayal has nothing to disclose.
Russell M. Cerejo, MD (Allegheny health Network) Dr. Cerejo has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Ischemaview.